Skip to content
LexBuild

New Animal Drugs; Change of Sponsor’s Name and Address

---
identifier: "/us/fr/01-22167"
source: "fr"
legal_status: "authoritative_unofficial"
title: "New Animal Drugs; Change of Sponsor’s Name and Address"
title_number: 0
title_name: "Federal Register"
section_number: "01-22167"
section_name: "New Animal Drugs; Change of Sponsor’s Name and Address"
positive_law: false
currency: "2001-09-05"
last_updated: "2001-09-05"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Health and Human Services Department"
document_number: "01-22167"
document_type: "rule"
publication_date: "2001-09-05"
agencies:
  - "Health and Human Services Department"
  - "Food and Drug Administration"
cfr_references:
  - "21 CFR Part 510"
fr_citation: "66 FR 46367"
fr_volume: 66
effective_date: "2001-09-05"
fr_action: "Final rule."
---

#  Names, addresses, and drug labeler codes of sponsors of approved applications.

**AGENCY:**

Food and Drug Administration, HHS.

**ACTION:**

Final rule.

**SUMMARY:**

The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor’s name and address for Baxter Pharmaceutical Products, Inc.

**DATES:**

This rule is effective September 5, 2001.

**ADDRESSES:**

Lonnie W. Luther, Center for Veterinary Medicine (HFV-102), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-0209.

**SUPPLEMENTARY INFORMATION:**

Baxter Pharmaceutical Products, Inc., 110 Allen Rd., Liberty Corner, NJ 07938, has informed FDA of a change of name and address to Baxter Healthcare Corp., 95 Spring St., New Providence, NJ 07974. Accordingly, the agency is amending the regulations in 21 CFR 510.600(c)(1) and (c)(2) to reflect the changes.

This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

**List of Subjects in 21 CFR Part 510**

Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.

**21 CFR Part 510**

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 510 is amended as follows:

**PART 510—NEW ANIMAL DRUGS**

1. The authority citation for 21 CFR part 510 continues to read as follows:

**Authority:**

21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

**21 CFR Part 510**

2. Section 510.600 is amended in the table in paragraph (c)(1) by revising the entry for “Baxter Pharmaceutical Products, Inc.” and in the table in paragraph (c)(2) by revising the entry for “010019” to read as follows:

§ 510.600

(c) * * *

(1) * * *

| Firm name and address | Drug labeler code |
| --- | --- |
|  |  |
| *         *         *         *         *         *         * |  |
| Baxter Healthcare Corp., 95 Spring St., New Providence, NJ 07974 | 010019 |
|  |  |
| *         *         *         *         *         *         * |  |

(2) * * *

| Drug labeler code | Firm name and address |
| --- | --- |
|  |  |
| *         *         *         *         *         *         * |  |
| 010019 | Baxter Healthcare Corp., 95 Spring St., New Providence, NJ 07974 |
|  |  |
| *         *         *         *         *         *         * |  |

Dated: August 23, 2001.

Claire M. Lathers,

Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.